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Serum paraoxonase 1 (PON1) in humans is a protein component of 
high-density  lipoprotein  (HDL)  particles  that  protects  against  oxidative 
damage, detoxifies toxic metabolites  of  organophosphorus pesticides and 
nerve agents and activates or inactivates specific drugs. It has been reported 
that PON1 gene coding region polymorphisms, L55M and Q192R, could 
influence both expression level and catalytic activity of PON1, and their 236                                                                                  GENETIKA, Vol. 42, No. 2, 235- 247, 2010 
link with a broad spectrum of diseases has been described. The aim of this 
study  was  to  determine  the  frequencies  of  PON1  coding  region 
polymorphisms Q192R and L55M in Serbian population. The most frequent 
alleles were Q (0.77) for Q192R and L (0.68) for L55M. Genotypes QQ 
(0.60) and LL (0.47) and combined genotype QQ/LL (0.26) were the most 
frequent in examined population.  
Key words: coding region polymorphisms, paraoxonase I, Serbian 
population 
 
INTRODUCTION 
 
Paraoxonase1  (PON1) is  a calcium-dependent  esterase  composed  of  354 
amino acids (45 kDa) belonging to a family of proteins that includes PON2 and 
PON3 (PRIMO-PARMO et al., 1996). The genes coding for the PON family are located 
on human chromosome 7 (q21.22). PON1 is synthesized in the liver and secreted 
into  the  blood  where  is  associated  with  high-density  lipoprotein (HDL) particles 
(MACKNESS et al., 1998). It is apparently associated with less than 10% of the total 
HDL. 
In vivo, a wide interindividual variation in serum PON1 concentration and 
activity  is  observed.  This  variation  is  largely  explained  by  common  genetic 
polymorphisms in the PON1 gene. Two polymorphisms are present in the PON1 
coding  sequence:  a  Gln(Q)/Arg(R)  substitution  at  position  192  (Q192R),  and  a 
Leu(L)/Met(M) substitution at position 55 (L55M) (COSTA et al., 2005). The PON1 
Q/R  polymorphism  significantly  affects  the  catalytic  efficiency  of  PON1.  Initial 
studies demonstrated that the R192 allozyme hydrolyzes paraoxon more readily than 
Q192  (COSTA  et  al.,  2005).  Further  studies  showed  that  this  polymorphism  was 
substrate dependent, as the Q192 alloform was found to hydrolyze diazoxon, sarin 
and soman more rapidly than R192 in vitro (DAVIES et al., 1996). Some studies have 
shown  that  under  physiological  conditions,  both  PON1  alloforms  hydrolyze 
diazoxon with nearly equivalent catalytic efficiencies (LI et al., 2000). The PON1 
L/M polymorphism has been associated with plasma PON1 protein levels, with M55 
being associated with low plasma PON1 (BLATTER et al., 1997; MACKNESS et al., 
1998). 
Nearly 200 polymorphisms have been described in the PON1 gene, some in 
the coding regions and others in introns and regulatory regions of the gene (JARVIK et 
al., 2003).  
Although  its  natural  substrate  is  still  unclear,  PON1  is  capable  of 
hydrolyzing  toxic  metabolites  of  organophosphorus  (OP)  compounds,  including 
paraoxon (a catabolite of the insecticide parathion), diazoxon and chlorpyrifos oxon, 
detoxifies  various  neurotoxic  agents  like  sarin  and  soman  and  hydrolyses  the 
aliphatic  lactones  such  as  dihydrocoumarin,  γ-butyrolactone  and  homocysteine 
thiolactone.  (BILLECKE  et  al.,  2000).  Several  experimental  studies  have  shown, 
however, that the effect of PON1 on the toxicity of OP compounds varies with the 
particular compound (COSTA et al., 2005).  I. PEJIN GRUBIŠA et al.: PARAXONASE I GENE POLYMORPHISM IN SERBIA                     237 
PON1  has  been  widely  investigated,  especially  for  its  involvement  in 
atherosclerosis  and  age-related  diseases.  The  Q192R  polymorphism  has  been 
associated  with  coronary  artery  disease,  stroke,  familial  hypercholesterolemia, 
Parkinson’s disease, and the onset of hypertension (MARCHEGIANI et al., 2008). Also, 
the L55 variant has been associated not only with variations in plasma levels of total 
and LDL cholesterol and in levels of PON1 message, protein, and activity toward 
paraoxon, but also with a variety of pathological conditions such as stroke, coronary 
artery disease (CAD), and Parkinson’s disease (MARCHEGIANI et al., 2008)  
PON1  is  assumed  to  be  involved  in  the  lipid  metabolism.  It  has  been 
reported to hydrolyze lipid peroxides in the arterial wall, preventing oxidation of low 
density lipoproteins, inactivates LDL-derived oxidized phospholipids once they are 
formed and prevents oxidation of HDL phospholipids (COSTA et al., 2003) and, thus, 
protecting against development of atherosclerosis (DURRINGTON et al., 2001). The 
analysis of literature on PON1 suggests that this gene is likely a leading actor in 
determining  the  rate  and  the  quality  of  the  aging  process,  probably  due  to  the 
capability to counteract oxidative stress (MARCHEGIANI et al., 2008). 
PON1 activity in infants is low compared to adults, rendering them with 
lower metabolic and antioxidant capacities. This difference was larger in children 
with genotypes associated with low PON1 activities (−108TT, 192QQ, −909CC). In 
mothers, PON1 activities were elevated at delivery and during pregnancy compared 
to 7 years later when they were not pregnant .Genetic control of PON1 enzymatic 
activity  varies  in  children  compared  to  adults and  is also  affected  by  pregnancy 
status (HUEN et al., 2010). 
Rojas-Garcia and coworkers (ROJAC-GARCIA et al., 2009) examined role of 
paraoxonase polymorphisms in the induction of micronucleus (MN) in paraoxon-
treated human lymphocytes. They found that paraoxon had no effect on cell viability, 
but caused a significant dose-dependent increase in MN frequency. A significant 
difference was observed in the MN frequency only in lymphocytes from individuals 
with  the  QQ  genotype  treated  with  5  µM  paraoxon.  In  another  study,  paraoxon 
showed no significant effects in a dose-dependent increase in the sister chromatide 
exchanges  (SCE) and  in  delay  in the  cell  cycle.  Also,  no significant  clastogenic 
effects and no difference in response were observed among individuals with different 
phenotypes of paraoxonase (SINGH et al., 1984). Serhatlioglu (SERHATLIOGLU et al., 
2003)  reported  a  decreased  level  of  paraoxonase  and  arylesterase  activities  in 
radiology workers exposed for more than five years to ionizing radiation  
In this study, we have evaluated the distribution of the PON1 Q192R and 
L55M polymorphisms in healthy Serbian population, considering the important role 
that these polymorphisms may play in the genetic susceptibility to toxicity with OP 
pesticides and in initiation and/or progression of different diseases. 
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Table 1. Allele frequencies of coding region polymorphisms in PON1 (Q192R i L55M) 
worldwide 
Q192R  L55M  Population 
Q  R  L  M 
References 
Europe 
Finnish  0.69  0.31  0.67  0.33  CLARIMON et al., 2004 
Dutch  0.68  0.32  0.63  0.37  LEUS et al., 2001 
Spanish  0.7  0.3  0.63  0.37  PARRA et al., 2006 
Italians  0.65  0.35  0.66  0.34  SARDO et al., 2005 
English  0.78  0.22  0.7  0.3  O'LEARY et al., 2005 
Turkish  0.69  0.31  0.7  0.3  AYNACIOGLU et al., 1999 
Croatian  0.77  0.23  0.66  0.34  GRDIC et al., 2008 
Germans  0.72  0.28  -  -  GARDEMANN et al., 2000 
French  0.76  0.24  -  -  RUIZ et al., 1995 
Northern Irish  0.712  0.288  -  -  HERRMANN et al., 1996 
Serbian  0.77  0.23  0.68  0.32  PRESENT STUDY 
Asia 
Japanese  0.4  0.6  0.96  0.04  MOHAMED and CHIA, 2008 
Koreans  0.38  0.620  0.94  0.06  HONG et al., 2001 
Chinese  0.42  0.58  0.95  0.05  MOHAMED and CHIA, 2008 
Indians  0.67  0.33  -  -  SANGHERA et al., 1997 
Iranian  0.69  0.31  0.59  0.41  SEPAHVAND et al., 2007 
Saudi Arabian  0.73  0.27  -  -  NOGUEIRA et al., 1993 
Israeli  0.67  0.33  0.61  0.39  BRYK et al., 2005 
America 
Caucasian-Americans  0.73  0.27  0.64  0.36  BROPHY et al., 2001 
Canadians  0.73  0.27  0.64  0.36  MCKEOWN-EYSSEN et al., 
2004 
African-Americans  0.68  0.32  0.80  0.2  ERLICH et al., 2006 
African-Americans  0.37  0.63  -  -  BROPHY et al., 2001 
Amazonian 
Ameridian tribes 
0.27  0.730  0.967  0.033  SANTOS et al., 2005 
European-Brazilians  0.693  0.307  0.609  0.391  ALLEBRANDT et al., 2002 
African-Brazilians  0.471  0.529  0.714  0.286  ALLEBRANDT et al., 2002 
Caribean-Hispanics  0.540  0.460  0.71  0.29  CHEN et al., 2003 
Mexicans  0.510  0.490  -  -  ROJAS-GARCIA et al., 2005 
Chileans 
NS 
ES 
 
0.569 
0.663 
 
0.431 
0.337 
 
- 
- 
 
- 
- 
ACUNÃ et al., 2004 
Peruvians  0.539  0.461  -  -  CATAÑO et al., 2006 
Africa 
Beninese  0.388  0.612  -  -  SCACCHI et al., 2003 
Ethiopians  0.592  0.408  -  -  SCACCHI et al., 2003 
Egyptians      -  -  EL-FASAKHANY et al., 2007 I. PEJIN GRUBIŠA et al.: PARAXONASE I GENE POLYMORPHISM IN SERBIA                     239 
MATRIAL AND METHODS 
The study included 122 healthy unrelated blood donors (78 male and 44 
female), aged 22−50 years, livingin in different Serbian regions.  
The study was approved by University Medical Hospital Zvezdara Ethics 
Committee. 
Venous blood samples were collected in EDTA-coated tubes and were used 
for determination of PON1 genotypes. Genomic DNA was extracted from EDTA-
anticoagulated blood using the DNeasy Blood & Tissue Kit (Qiagen). Isolated DNA 
was stored at +4 °C until further analysis. 
PON1  L55M  and  Q192R  genotyping  was  performed  using  polymerase 
chain reaction-restriction fragment length polymorphism analysis (PCR-RFLP). The 
primers  used  for  the  amplification  of  the  both  polymorphism  were  described  by 
Rantala and coworkers (RANTALA et al., 2002). PCR mixture (total volume 20 µl) 
contained PyroStart
TM Fast PCR Master Mix (2X-concentrated solution containing 
hot start Taq DNA polymerase, reaction buffer, MgCl2 , and dNTP, Fermentas Life 
Sciences), 0.5µM of each primer (Metabion) and 0.2µg of genomic DNA. The PCR 
reaction was performed for each polymorphism. PCR thermocycling was suited for 
PyroStart
TM Fast PCR Master Mix Protocol (provided by the manufacturer).  
Digestion  of  PCR  products  was  performed  as  previously  described 
(RANTALA et al., 2002) with slight modifications. The L55M (169-bp) PCR product 
was  digested  with  2,5  U  of  Hin1II  (Fermentas  Life  Sciences)  at  37°C  for  3h. 
Digestion resulted in 127- and 42-bp fragments for the M allele and a nondigested 
169-bp fragment for the L allele. The Q192R (99-bp) PCR product was digested with 
2,5 U of BspPI (Fermentas Life Sciences) at 37°C for 3h. Digestion with BspPI 
resulted  in  63-  and  36-bp  fragments  for  the  R  allele  and  a  nondigested  99-bp 
fragment for the Q allele. The digested fragments were separated on 3 % agarose gel, 
stained with ethidium bromide (0.5 µg/ml) and visualized under UV light.  
Genotype  and  allele  frequencies  were  determinated  by  counting-method, 
and Hardy-Weinberg’s equilibrium was tested by the Chi-square test (χ 
2 test). 
 
RESULTS 
This  study  represents  genotype  and  allele  frequencies  for  coding  region 
polymorphisms of the PON1 gene, Q192R and L55M, in Serbian population. 
Results are summarized in Table 2 and Table 3. The observed frequencies 
for Q, R, L and M alleles were 77%, 23%, 68% and 32%, respectively (Table 1).  
The  most  common  genotype  in  Serbian  population  was  QQ  (60%)  for 
Q192R  polymorphism  and  LL  (47%)  for  L55M  polymorphism,  and  the  least 
common was RR (6%) for both polymorphisms (Table 1).  
Frequencies  of  combined  genotypes  are  shown  in  Table  2.  The  most 
frequent  genotype  combinations  were  QQ/LL  (26%)  and  QQ/LM  (25%) 
respectively. The least frequent combined genotypes were both RR/LM and RR/MM 
(1%). 
According to results of χ 
2 test, Serbian population is in Hardy-Weinberg 
equilibrium for examined loci.  240                                                                                  GENETIKA, Vol. 42, No. 2, 235- 247, 2010 
 
 
Table 2. Allele and genotype frequencies of coding region polymorphisms of PON1 gene in 
Serbian population  
 
Frequency  Frequency  Polymorphism  Allele 
N=244  n  % 
Genotype 
N=122  n  % 
 
PON1 Q192R 
Q 
R 
187 
57 
77 
23 
QQ 
QR 
RR 
73 
41 
8 
60 
34 
6 
 
PON1 L55M 
L 
M 
165 
79 
68 
32 
LL 
LM 
MM 
54 
51 
14 
47 
42 
11 
N- number of examinated alleles and genotypes; n - number of individuals having a certain allele and 
genotype  
 
 
 
Table 3. Combined genotypes frequencies of coding region polymorphisms of PON1 
gene in Serbian population 
 
Frequency  Combined genotype 
n  % 
QQ/LL 
QQ/LM 
QQ/MM 
QR/LL 
QR/LM 
QR/MM 
RR/LL 
RR/LM 
RR/MM 
32 
31 
10 
19 
19 
3 
6 
1 
1 
26 
25 
8 
16 
16 
2 
5 
1 
1 
n - number of individuals having a certain genotype  
 
 
 I. PEJIN GRUBIŠA et al.: PARAXONASE I GENE POLYMORPHISM IN SERBIA                     241 
DISCUSSION 
To our knowledge, this is the first study reporting the frequency of PON1 
polymorphisms Q192R and L55M in Serbian population.  
Our findings are in agreement with previously reported data for European 
population, which showed predominance of Q192 and L55 alleles over R192 and 
M55  alleles.  (Table  1).  In  Serbs,  for  the  most  frequent  allelles,  Q192  and  L55, 
frequencies were 0.77 and 0.68 respectively, and for R192 and M55 alleles were 
0.23 and 0.32 (Table 2). 
Allele Q192 is more frequent in Indian, Iranian, Saudi Arabian and Israeli 
populations in Asia, in Canadian, European-Brazilians and in much more American 
and in Egyptian populations. It's slightly higher in Caribean-Hispanics, Mexicans, 
Chileans, Peruvians and Ethiopians (Table 1). 
Allele R192 is predominant in Japanese, Korean, Chinese and Malaysian 
populations in Asia, in Afro–Americans where we have contradictory data, and in 
Amazonian-Ameridiand tribes in America, and also in Beninese in Africa (Table 1). 
From the PON1 sequences of chimpanzees and an orangutan, Koda and coworkers 
(KODA et al., 2004) found that the ancestral type of codon 192 was R. 
The variable distribution of allele frequencies appeared to be dependent on 
geographic locations (SCACCHI et al., 2003) perhaps due to genetic drift, as well as 
ethnic groups (SANGHERA et al., 1998).  
The Q192R polymorphism significantly affects the catalytic efficiency of 
PON1 associated with HDL in blood. Studies showed that this polymorphism was 
substrate dependent, as the Q192 allozyme was found to hydrolyze diazoxon, sarin 
and soman more rapidly than R192 in vitro (DAVIES et al., 1996), and R192 allozyme 
hydrolyzes  paraoxon  more  readily  than  Q192  (COSTA  et  al.,  2005).  Also,  Q192 
hydrolyses phospholipid and cholesteryl ester hydroperoxides more efficiently than 
the R192 allozyme. (AVIRAM et al., 1999).  
It has been shown that HDL isolated from RR homozygotes is less effective 
in  protecting  LDL  against  lipid  peroxidation  than  HDL  from  either  QQ  or  QR 
genotypes  (MACKNESS  et  al.,  1998).  Genotype  QQ  may  have  protective  effects 
against oxidative stress. Paraoxonase is lipid-dependent enzyme and its conformation 
within the hydrophobic environment of HDL is crucial for its activity (SORENSON et 
al., 1999). Phospholipids stabilize PON1 enzyme and are required for its binding to 
HDLs lipoprotein surface. So, lipid peroxidation of that surface can affect PON1s 
binding and decrease enzyme activity.  
LDL oxidation is a key process in the pathophysiology of atherosclerosis 
and  the  onset  of  cardiovascular  diseases  (STEINBERG  et  al.,  1989),  and  various 
studies of Caucasians have associated PON1 Q192R polymorphism with coronary 
heart disease risk, whereas others have not (RUIZ et al., 1995; SERRATO et al., 1995). 
For codon 55 polymorphism, populations worldwide show predominance of 
L55 over M55 allele, and Japanese, Korean, Chinese, Malaysian and Amazonian-
Ameridian tribes show a very low frequencies of it (Table 1). The generally low 
frequency of the M allele was such that in some studies the MM genotype was not 
observed at all (SANTOS et al., 2005). In Serbian population, frequencies of LL, LM 242                                                                                  GENETIKA, Vol. 42, No. 2, 235- 247, 2010 
and MM genotypes were 0.47, 0.42 and 0.11 respectively. The L55M mutation may 
considerably affect PON1's stability and thereby account for the lower enzymatic 
activity (MACKNESS et al., 1998). This is due to the key role of L55 in packing the 
propeller's central tunnel, and of its neighboring residues (Glu53 and Asp54), which 
ligate  both  Ca1 and  Ca2  –  'catalytic'  and  'structural'  calcium  iones,  respectively. 
(HAREL et al., 2004). M55 isoform is unstable form unresistant to proteolysis, so we 
assume  that  allele  M  is  not  favored  in  human  populations,  but  it  is  kept  in 
populations in heterozygous individuals.  
Unlike some examed populations (GRDIĆ et al., 2008; POH and MUNIANDY, 
2007), all nine possible genotype combinations of two polymorphisms were seen in 
this population. (Table 3). The most frequent combinations were QQ/LL (0.26) and 
QQ/LM (0.25), and the leas frequent were RR/LM (0.01) and RR/MM (0.01). 
As a result of ionizing radiation, Serhatlioglu (SERHATLIOGLU et al., 2003) 
reported a decreased level of paraoxonase and arylesterase activities in irradiated 
workers, and earlier cytogenetic analyses showed persistence of unstable structural 
chromosome aberrations, both dicentric (dic) and centric ring chromosomes (cR), 
long time after irradiation (PENDIC et al., 1980). The results from Schröder et al, 
(SCHRÖDER et al., 2003) obtained from blood lymphocyte analyses from Gulf War 
and Balkan wars veterans exposed to depletet uranium (DU), showed statistically 
significant increase in the frequency of dic and cR. This information raised concern 
with respect to potential biological hazard from DU exposure on Balkan-countries 
populations,  especially  because  of  decreased  antioxidant/detoxifying  capacity  of 
PON1  enzyme  and  chromosome  unstabilities.  In  same  study  (SCHRÖDER  et  al., 
2003),  frequency  of  SCEs  was  decreased  compared  with  control.  SCE  assay  is 
accepted to measure genotoxic exposure only to chemical toxicants, and ionizing 
radiation is inefficient in SCE production (BARJAKTAROVIĆ, 1984). MILLER et al 
(2002)  have  demonstrated  in  in  vitro  experimented  that  DU  is  able  to  catalyse 
reactions of hydrogen peroxide and ascorbate, generating oxidative DNA damage 
that  can  induce  carcinogenic  lesions.  Probably,  same  reactions  can  lead  to  lipid 
peroxidation of HDL surface and decreased enzyme activity. 
The results obtained in study of Rojas-Garcia and co-workers (ROJAC-GARCIA et al., 
2009) suggest that PON1 genotype might have an important role in the identification 
of  individuals  at  risk  for  cancer  development  due  to  occupational  exposure  to 
pesticides, because they observed a significant difference in the MN frequency only 
in lymphocytes from individuals with the QQ genotype treated with 5 µM paraoxon. 
Enhanced sensitivity to the chromosome-damaging effects of ionizing radiation is a 
feature of many cancer-predisposing conditions, but to our knowledge, there is no 
data linking PON1 genotypes with higher sensitivity to ionizing radiation. 
Paraoxonase 1 is a multi-purpose enzyme that has been shown to perform a 
variety of jobs in the body, including ridding the arteries of plaque-forming clumps 
of  LDL  that  lead  to  artheriosclerosis,  and  degrading  toxic  chemicals  such  as 
pesticides and nerve gases. Results from this population-based study provide a basis 
for future examining the possible association of PON1 gene polymorphisms with the 
development and/or progression of various diseases in Serbian population, and to I. PEJIN GRUBIŠA et al.: PARAXONASE I GENE POLYMORPHISM IN SERBIA                     243 
examine  link  between  PON1  genotype  and  ionisation  irradiation  inside  Serbia 
borders. 
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I z v o d 
   
Serumska  paraoksonaza  1  (PON1)  kod  ljudi  je  proteinska  komponenta 
lipoproteina visoke gustine (HDL) koja štiti od oksidativnog oštećenja, detoksifikuje 
toksične  metabolite  organofosfatnih  pesticida  i  bojnih  otrova  i  aktivira/inaktivira 
pojedine  vrste  lekova.  Uočeno  je  da  polimorfizmi  u  kodirajućem  regionu  PON1 
gena, L55M i Q192R, mogu uticati i na nivo ekspresije i na katalitičku aktivnost 
PON1, a i opisane su njihove povezanosit sa pojavom širokog spektra oboljenja. Cilj 
ove  studije  je bio da  se odrede učestalosti polimorfizama u  kodirajućem regionu 
PON1  gena,  L55M  i  Q192R,  u  populaciji  ljudi  koji  žive  na  teritoriji  Republike 
Srbije. Prema našim rezultatima, najzastupljeniji aleli su Q (0.77) za Q192R i L 
(0.68) za L55M. Genotipovi QQ (0.60) i LL (0.47) i kombinovani genotip QQ/LL 
(0.26) su najzastupljeniji u srpskoj populaciji. 
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